The combined annual global market size of the indications we are targeting is over US$110 billion, which is derived from the total addressable market for the treatment of OSA, TBI, concussion, rheumatoid arthritis, inflammatory bowel disease, inflammatory lung conditions (ARDS, COPD, Asthma, Bronchitis) and GAD. Success in the clinical development programmes will not only provide benefit to patients suffering from untreated medical conditions, but also significant economic potential for shareholders.
The potential is limitless
Incannex are global leaders in the development of novel medicinal cannabinoid compounds and psychedelic therapies.
The potential is limitless
Incannex are global leaders in the development of novel medicinal cannabinoid compounds and psychedelic therapies.
Boundless medical potential
Undertaking six clinical programs targeting conditions for patients with unmet medical needs.
Boundless medical potential
Undertaking six clinical programs targeting conditions for patients with unmet medical needs.
Unrivalled economic potential
The combined annual global market size of the indications we are targeting is over US$110 billion.
Unrivalled economic potential
The combined annual global market size of the indications we are targeting is over US$110 billion.


Clinical Development Pathway
Incannex is a cannabinoid and psychedelic compound medicine development company undertaking six clinical programs guided by our medical advisory board. These 6 programs are targeting conditions for patients with unmet medical needs. This means we have the ability to help billions of people around the planet. The potential is limitless.
US$110 billion potential.


Latest results and presentations
Incannex receives key ethics approval to start Phase 1 clinical trial of multi-use anti-inflammatory drug
Health & Biotech Special Report: Incannex has achieved approval to start a milestone clinical trial into its multi-use,...Shares in Incannex jump 11% after positive US FDA meet over sleep apnoea drug
Health & Biotech Special Report: In another significant milestone, Incannex Healthcare (ASX:IHL) says it’s received positive feedback with...Incannex shares reach a high of 44c on landmark $125m deal to buy US cannabinoid pioneer APIRx
Health & Biotech Special Report: Incannex shares have rocketed higher today on news it has signed a formal...Knocking heads: Incannex achieves key concussion breakthrough
Health & Biotech Special Report: IHL’s novel drug IHL-216A could be the holy grail in concussion treatment, with...With $40m in the bank and an exciting product suite, Incannex targets game-changing US acquisition for even more growth
Health & Biotech Special Report: The company had a busy quarter of clinical research breakthroughs, listing on NASDAQ...Australia’s top 20 cannabis companies
Health & Biotech After its share price hit an all-time high in early 2022, the newly joint-listed medicinal...Incannex meets with US FDA on development of IHL-42X
Health & Biotech Clinical-stage cannabinoid pharmaceutical development company Incannex Healthcare (ASX: IHL) has completed a pre-investigational new drug...Incannex IHL-42X lowered apnoea hypopnea index score in OSA
Health & Biotech Incannex Healthcare’s IHL-42X lowered apnoea hypopnea index score in OSA sufferers during clinical study. During a...Subscribe
Stay up to date with Incannex’s research and development program.